SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGNX -- MacroGenics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (69)11/7/2017 12:46:28 PM
From: scaram(o)uche  Respond to of 188
 
>> saying folks who sold a few weeks ago are now chasing TRIL stock into bubbliness, or what? <<

No, I'm saying that, if the observation of bystander efficacy for intratumoral injection holds, it'll be 100X from here. I assign odds at 1:100.

;-)



To: tuck who wrote (69)11/7/2017 12:48:34 PM
From: scaram(o)uche  Respond to of 188
 
>> I could easily see it coming back some. <<

I could easily see a partner.



To: tuck who wrote (69)11/7/2017 12:55:46 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 188
 
We were all surprised by the size of the 012 deal. I'm not going to try to parse early results versus Keytruda et al., seems like a losing proposition.

I am interested in knowing if 012 contributed the variable region to MGD013. Anybody know? TIA.



To: tuck who wrote (69)11/9/2017 10:13:47 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 188
 
nice call!

(not enjoying it at all! ;-)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News